Novel Circulating Tumor Cells Blood Assay for the Clarification of 4-10 ng/mL PSA Results - See-Tong Pang

July 3, 2018

(Length of Discussion: 15 min)

Tom Keane and See-Tong Pang discuss the results of a prospective clinical study utilizing a novel circulating tumor cells (CTC) blood assay to clarify PSA results in 200 men who present with a PSA of 4ng/ml-10ng/ml.  The CellMax CTC Platform is used to isolate CTCs to assess NPV and PPV for Gray Zone patients.  Isolated CTCs may also be analyzed for the presence of prognostic genomic alterations and with a low cost may enable broad global access.  The discussion then evolves to a brief comparison of a similar test also used to detect cancer in this patient population, each sharing their expert opinions.


Thomas E. Keane, MBBCh, FRCSI, FACS

See-Tong Pang, MD Department of Urology, Chang Gung University and Hospital. Linkou, Taoyuan, Taiwan.  Dr. Pang specializes in urological cancers, laparoscopic surgery, da Vinci robotic surgery, and cryosurgery.